Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,934 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00722137 | Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma | completed | Phase 3 | 487 | Millennium Pharmaceuticals, Inc.INDUSTRY | 29 | Jul 12, 2018 | clinicaltrials |
| NCT00003888 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer | completed | Phase 3 | 359 | European Organisation for Research and Treatment of Cancer - EORTC |
| 15 |
| Jul 9, 2018 |
| clinicaltrials |
| NCT00056056 | Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides | terminated | Phase 3 | 93 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 13 | Jul 9, 2018 | clinicaltrials |
| NCT00103168 | Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor | completed | Phase 3 | 908 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Jul 9, 2018 | clinicaltrials |
| NCT01098656 | Lenalidomide Maintenance Post-debulking in Advanced CTCL | terminated | Phase 3 | 21 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Jul 9, 2018 | clinicaltrials |
| NCT01582061 | An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.(SEASCAPE) | completed | Phase 3 | 104 | Novartis PharmaceuticalsINDUSTRY | 11 | Jun 19, 2018 | clinicaltrials |
| NCT01582672 | Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma(ADAPT) | terminated | Phase 3 | 462 | Argos TherapeuticsINDUSTRY | 8 | Jun 14, 2018 | clinicaltrials |
| NCT01767467 | Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers | completed | Phase 3 | 568 | GlaxoSmithKlineINDUSTRY | 21 | Jun 6, 2018 | clinicaltrials |
| NCT01571284 | Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen | completed | Phase 3 | 781 | SanofiINDUSTRY | 23 | Apr 17, 2018 | clinicaltrials |
| NCT00117572 | Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)(DeCIDE) | completed | Phase 3 | 285 | University of ChicagoOTHER | 5 | Apr 9, 2018 | clinicaltrials |
| NCT01137682 | Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly(PAOLA) | completed | Phase 3 | 198 | Novartis PharmaceuticalsINDUSTRY | 18 | Apr 5, 2018 | clinicaltrials |
| NCT00988208 | Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer(Mainsail) | completed | Phase 3 | 1,059 | CelgeneINDUSTRY | 21 | Apr 4, 2018 | clinicaltrials |
| NCT01605227 | Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100(COMET-1) | completed | Phase 3 | 1,028 | ExelixisINDUSTRY | 14 | Mar 14, 2018 | clinicaltrials |
| NCT01345682 | LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy | completed | Phase 3 | 483 | Boehringer IngelheimINDUSTRY | 19 | Feb 15, 2018 | clinicaltrials |
| NCT01002248 | Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients | terminated | Phase 3 | 135 | AEterna ZentarisINDUSTRY | 9 | Feb 9, 2018 | clinicaltrials |
| NCT00364351 | Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy | completed | Phase 3 | 1,574 | Genzyme, a Sanofi CompanyINDUSTRY | 22 | Jan 25, 2018 | clinicaltrials |
| NCT00950300 | A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer | completed | Phase 3 | 596 | Hoffmann-La RocheINDUSTRY | 26 | Jan 23, 2018 | clinicaltrials |
| NCT02134015 | Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)(HER3-Lung) | terminated | Phase 3 | 145 | Daiichi SankyoINDUSTRY | 10 | Jan 23, 2018 | clinicaltrials |
| NCT01646021 | Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy | completed | Phase 3 | 280 | Janssen Research & Development, LLCINDUSTRY | 21 | Jan 19, 2018 | clinicaltrials |
| NCT01601314 | Perioperative Magnesium Sulphate as a Cerebral Protector in Neurosurgical Patients(MAGNA) | completed | Phase 3 | 55 | Sara VareaOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT01480479 | Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma(ACT IV) | completed | Phase 3 | 745 | Celldex TherapeuticsINDUSTRY | 24 | Jan 16, 2018 | clinicaltrials |
| NCT00562965 | Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL) | terminated | Phase 3 | 29 | PfizerINDUSTRY | 14 | Jan 9, 2018 | clinicaltrials |
| NCT01377922 | A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) | completed | Phase 3 | 38 | Catalyst Pharmaceuticals, Inc.INDUSTRY | 8 | Jan 4, 2018 | clinicaltrials |
| NCT01307397 | A Study of Vemurafenib in Participants With Metastatic Melanoma | completed | Phase 3 | 3,219 | Hoffmann-La RocheINDUSTRY | 44 | Dec 18, 2017 | clinicaltrials |
| NCT02328716 | Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma(CARCINOHIPEC) | unknown | Phase 3 | 32 | Fundacion para la Formacion e Investigacion Sanitarias de la Region de MurciaOTHER | 1 | Dec 13, 2017 | clinicaltrials |
| NCT01015118 | LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer | completed | Phase 3 | 1,366 | Boehringer IngelheimINDUSTRY | 22 | Dec 7, 2017 | clinicaltrials |
| NCT01345669 | LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy | terminated | Phase 3 | 617 | Boehringer IngelheimINDUSTRY | 29 | Dec 7, 2017 | clinicaltrials |
| NCT01722487 | Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL | completed | Phase 3 | 269 | Pharmacyclics LLC.INDUSTRY | 16 | Nov 30, 2017 | clinicaltrials |
| NCT01632904 | Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study | completed | Phase 3 | 110 | Incyte CorporationINDUSTRY | 7 | Nov 14, 2017 | clinicaltrials |
| NCT01154140 | A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung(PROFILE 1014) | completed | Phase 3 | 343 | PfizerINDUSTRY | 31 | Nov 6, 2017 | clinicaltrials |
| NCT01387269 | Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1) | completed | Phase 3 | 484 | Helsinn Therapeutics (U.S.), IncINDUSTRY | 16 | Oct 27, 2017 | clinicaltrials |
| NCT01939223 | Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-Controlled Phase-III STudy(COAST) | terminated | Phase 3 | 25 | BayerINDUSTRY | 14 | Oct 20, 2017 | clinicaltrials |
| NCT00424047 | A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 351 | CelgeneINDUSTRY | 15 | Oct 19, 2017 | clinicaltrials |
| NCT01649856 | A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma | completed | Phase 3 | 572 | Hoffmann-La RocheINDUSTRY | 27 | Oct 11, 2017 | clinicaltrials |
| NCT01227889 | A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma | completed | Phase 3 | 251 | GlaxoSmithKlineINDUSTRY | 12 | Oct 4, 2017 | clinicaltrials |
| NCT01916252 | Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old(GEM2012MENOS65) | completed | Phase 3 | 460 | PETHEMA FoundationOTHER | 1 | Sep 27, 2017 | clinicaltrials |
| NCT00943826 | A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma | completed | Phase 3 | 921 | Hoffmann-La RocheINDUSTRY | 24 | Sep 25, 2017 | clinicaltrials |
| NCT01593228 | Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial | completed | Phase 3 | 37 | SanofiINDUSTRY | 4 | Sep 19, 2017 | clinicaltrials |
| NCT01351415 | A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 485 | Hoffmann-La RocheINDUSTRY | 18 | Sep 18, 2017 | clinicaltrials |
| NCT01395914 | Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3) | completed | Phase 3 | 513 | Helsinn Therapeutics (U.S.), IncINDUSTRY | 17 | Sep 14, 2017 | clinicaltrials |
| NCT01416181 | A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis(ASCEND in SPMS) | terminated | Phase 3 | 889 | BiogenINDUSTRY | 17 | Sep 11, 2017 | clinicaltrials |
| NCT00348140 | Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease(REFLECT-3) | completed | Phase 3 | 1,468 | GlaxoSmithKlineINDUSTRY | 22 | Sep 5, 2017 | clinicaltrials |
| NCT00241722 | Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain | completed | Phase 3 | 805 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 17 | Aug 30, 2017 | clinicaltrials |
| NCT01516736 | Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim(PROTECT2) | completed | Phase 3 | 308 | SandozINDUSTRY | 8 | Aug 30, 2017 | clinicaltrials |
| NCT01074047 | Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML) | completed | Phase 3 | 488 | CelgeneINDUSTRY | 18 | Aug 29, 2017 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials